U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H16O6
Molecular Weight 388.3695
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PAMOIC ACID

SMILES

OC(=O)C1=CC2=C(C=CC=C2)C(CC3=C4C=CC=CC4=CC(C(O)=O)=C3O)=C1O

InChI

InChIKey=WLJNZVDCPSBLRP-UHFFFAOYSA-N
InChI=1S/C23H16O6/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h1-10,24-25H,11H2,(H,26,27)(H,28,29)

HIDE SMILES / InChI

Molecular Formula C23H16O6
Molecular Weight 388.3695
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27064272 | https://www.ncbi.nlm.nih.gov/pubmed/20580560

Pamoic acid, also called embonic acid, is a naphthoic acid derivative, used as a counter ion of a drug compound to increase the solubility of the drug in water. Pamoic acid has agonist activity for the orphan G protein-coupled receptor GPR35 by which it activates ERK and beta-arrestin2, and causes antinociceptive activity. Although (like other drug salts) it has been considered an inactive compound by the FDA.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
79.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.
2009-11-29
Second-generation antipsychotic long-acting injections: systematic review.
2009-11
Diagnosis and control of anthelmintic-resistant Parascaris equorum.
2009-09-25
Anthelmintic resistance in cyathostomin populations from horse yards in Italy, United Kingdom and Germany.
2009-09-25
The control of hookworm infection in China.
2009-09-24
Synergistic effect of febantel and pyrantel embonate in elimination of Giardia in a gerbil model.
2009-08
Treatment of naturally occurring, asymptomatic Giardia sp. in dogs with Drontal Plus flavour tablets.
2009-08
Fixed drug eruption resulting from fluconazole use: a case report.
2009-07-06
Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres.
2009-06
Field effectiveness of pyrantel and failure of Parascaris equorum egg count reduction following ivermectin treatment in Italian horse farms.
2009-04-06
Olanzapine pamoate - blockbuster or damp squib?
2009-04
Ascariasis-associated worm encephalopathy in a young child.
2009-04
Density-dependent effects on the weight of female Ascaris lumbricoides infections of humans and its impact on patterns of egg production.
2009-02-10
Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic.
2009-01
Influence of Bi 58 Nowy (38% dimethoate) on pyrantel embonate concentration in the liver of rats.
2009
The old and new therapeutic approaches to the treatment of giardiasis: where are we?
2009
The little-known scenario of anthelmintic resistance in equine cyathostomes in Italy.
2008-12
Highly pathogenic avian influenza virus (H5N1) infection in red foxes fed infected bird carcasses.
2008-12
Education and imaging. Gastrointestinal: ascariasis.
2008-11
Gateways to clinical trials.
2008-10
Efficacy of Drontal Flavour Plus (50 mg praziquantel, 144 mg pyrantel embonate, 150 mg febantel per tablet) against Giardia sp in naturally infected dogs.
2008-10
Micromolar concentration of kynurenic acid in rat small intestine.
2008-08
Evaluation of parasiticidal activity of fenbendazole, ivermectin, oxibendazole, and pyrantel pamoate in horse foals with emphasis on ascarids (Parascaris equorum) in field studies on five farms in Central Kentucky in 2007.
2008-07
Field studies indicating reduced activity of ivermectin on small strongyles in horses on a farm in Central Kentucky.
2008-06
Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis.
2008-04-23
Structural insights on the pamoic acid and the 8 kDa domain of DNA polymerase beta complex: towards the design of higher-affinity inhibitors.
2008-04-16
Anthelmintic prescribing patterns of a sample of general practitioners from selected areas in the colombo district of sri lanka.
2008-04
Controlling soil-transmitted helminthiasis in pre-school-age children through preventive chemotherapy.
2008-03-26
D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia.
2008-01
Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy.
2008
Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
2008
Occurrence of anthelmintic resistant equine cyathostome populations in central and southern Italy.
2007-12-14
Chitotriosidase deficiency is not associated with human hookworm infection in a Papua New Guinean population.
2007-12
Necrosis avidity of (99m)Tc(CO)3-labeled pamoic acid derivatives: synthesis and preliminary biological evaluation in animal models of necrosis.
2007-10-13
Study (1991 to 2001) of drug-resistant Population B small strongyles in critical tests in horses in Kentucky at the termination of a 40-year investigation.
2007-08
Revalidation and rationale for high pKa values of unconjugated bilirubin.
2007-05-02
Macrocyclic lactone-resistant Parascaris equorum on stud farms in Canada and effectiveness of fenbendazole and pyrantel pamoate.
2007-04-30
Field evaluation of the efficacy and the safety of a combination of oxantel/pyrantel/praziquantel in the treatment of naturally acquired gastrointestinal nematode and/or cestode infestations in dogs in Europe.
2007-04-10
Comparison of various anthelmintic therapies for the treatment of Trypanoxyuris microon infection in owl monkeys (Aotus nancymae).
2007-04
Parasite field study in central Kentucky on thoroughbred foals (born in 2004) treated with pyrantel tartrate daily and other parasiticides periodically.
2007-02
A field study on the effect of some anthelmintics on cyathostomins of horses in sweden.
2007-01
Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35.
2006-09-18
Determination of antihelminthic drug pyrantel pamoate in bulk and pharmaceutical formulations using electro-analytical methods.
2006-09-15
Cyathostomes in horses in Canada resistant to pyrantel salts and effectively removed by moxidectin.
2006-08-31
Dose-confirmation studies of the cestocidal activity of pyrantel pamoate paste in horses.
2006-06-15
Pinning down pinworms.
2006-05
[A case of drug eruption induced by hydroxyzine pamoate].
2006-01
Heart failure caused by hookworm infection possibly associated with organic food consumption.
2006
Residues of dimethoate in the liver and AchE activity in blood of rats after exposure to dimethoate, and dimethoate and pyrantel embonate.
2006
Target animal safety and tolerance study of pyrantel pamoate paste (19.13% w/w pyrantel base) administered orally to horses.
2005
Patents

Sample Use Guides

Abdominal Constriction Test in Mice were used for Pamoic acid activity evaluation. Four groups of 10 male, Swiss-Webster mice (30–35 g; Ace Animals, Inc., Boyertown, PA) were used. They were then injected with saline or one of three doses of pamoic acid disodium (25, 50, and 100 mg/kg s.c.). Twenty minutes later, each mouse was challenged with 0.6% acetic acid (0.30 ml/30 g animal i.p.) and, after an additional 5 min, was observed over the subsequent 10 min for abdominal writhing behavior.
Route of Administration: Other
U2OS cells transiently expressing human GPR35b and _arr2-GFP or HEK 293 cells transiently expressing mouse GPR35 and beta arr2-GFP were used 48 h after transfection. U2OS cells permanently expressing HA-GPR35a and _arr2-GFP (UGPR35_) were used for most experiments. Cells were plated onto coverslips, placed in 24-well plates, and pretreated for 1 h with 0.02 mg/ml poly-Dlysine. Cells were maintained at 37°C in 5% CO2 until ready for experiments (80–85% confluent) and washed once with HBSS before drug application and experiments were performed in HBSS. Agonist stimulated redistribution of _arr2-GFP was assessed after drug treatment for 40 min. Experiments involving antagonist were done with 15 min preincubation of antagonist for both the stable UGPR35 cells and the transiently transfected mouse GPR35 HEK293 cells. To examine reversibility of the antagonist, cells were preincubated with 100 nM CID2745687 for 10 min, then washed with HBSS five times for 5 min each before adding 1 mkM pamoic acid. Cells were then fixed with 4% paraformaldehyde for 20 min at room temperature followed by three washes with HBSS.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:27:37 GMT 2025
Edited
by admin
on Mon Mar 31 21:27:37 GMT 2025
Record UNII
7RRQ8QZ38N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PAMOIC ACID
MI   USP-RS   WHO-DD  
Common Name English
NSC-30188
Preferred Name English
Pamoic acid [WHO-DD]
Common Name English
4,4'-METHYLENEBIS(3-HYDROXY-2-NAPHTHALENECARBOXYLIC ACID)
Systematic Name English
4,4'-METHYLENEDI(3-HYDROXY-2-NAPHTHOIC ACID)
Systematic Name English
PAMOIC ACID [MI]
Common Name English
PYRANTEL EMBONATE RELATED COMPOUND PAMOIC ACID [USP IMPURITY]
Common Name English
PAMOIC ACID [USP-RS]
Common Name English
EMBONIC ACID
Common Name English
Code System Code Type Description
MERCK INDEX
m8376
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY Merck Index
RS_ITEM_NUM
1493000
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
SMS_ID
100000079735
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
WIKIPEDIA
PAMOIC ACID
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
FDA UNII
7RRQ8QZ38N
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
NSC
30188
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
EVMPD
SUB14746MIG
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
PUBCHEM
8546
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
CHEBI
50186
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
EPA CompTox
DTXSID9048984
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
CAS
130-85-8
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
ECHA (EC/EINECS)
204-998-0
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
MESH
C004368
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> IMPURITY
NO peak value listed in USP-NF
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP